S1193
Clinical - Urology
ESTRO 2026
Hassan 2 , Suneil Jain 17 , Susan Campbell 18 , Swechha Sirohi 2 , Vicki Hinder 19 , Clare Cruickshank 2 , Emma Hall 2 1 Department of Oncology, The Clatterbridge Cancer Centre, Wirral, United Kingdom. 2 Clinical Trial and Statistics Unit, Institute of Cancer Research, London, United Kingdom. 3 Department of Oncology, The Royal Marsden NHS Trust, London, United Kingdom. 4 Department of Oncology, Leeds Cancer Centre, Leeds, United Kingdom. 5 Department of Oncology, Velindre Cancer Centre, Cardiff, United Kingdom. 6 National RTQA, Radiotherapy Trials Quality Assurance (RTTQA) Group, Wirral, United Kingdom. 7 National RTQA, Radiotherapy Trials Quality Assurance (RTTQA) Group, London, United Kingdom. 8 Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. 9 Department of Oncology, Torbay & South Devon NHSFT, Torquay, United Kingdom. 10 Department of Oncology, Addenbrooke’s Hospital, Cambridge, United Kingdom. 11 Department of Oncology, Freeman Hospital, Newcastle, United Kingdom. 12 Clinical Oncology, North Middlesex Hospital, Royal Free London NHS Trust, London, United Kingdom. 13 Clinical Oncology, United Lincolnshire Teaching Hospitals Trust, Lincoln, United Kingdom. 14 Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, United Kingdom. 15 Medical Physics and Engineering, St James’s University Hospital, Leeds, United Kingdom. 16 Department of Oncology, Ipswich Hospital, Ipswich, United Kingdom. 17 Johnston Cancer Research Centre, Queen's University Belfast, Belfast, United Kingdom. 18 Patient and Public Representative, c/o ICR-CTSU, London, United Kingdom. 19 Ex-Clinical Trial and Statistics Unit, Institute of Cancer Research, London, United Kingdom Purpose/Objective: With conventionally fractionated radiotherapy, focal boosting of the intraprostatic tumour(s) improves biochemical control without significantly increasing toxicity. Risks and benefits of focal boosting with a 20- fraction schedule are unclear. We present side effect Men recruited from 38 UK centres with NCCN intermediate/high risk prostate cancer were randomised to prostate radiotherapy (P; control); prostate plus pelvic node radiotherapy (PPN), P with boost (P-B); or PPN with boost (PPN-B) stratified by type of boost (Table 1). (Where tumour unsuitable or boosting not available, randomisation was to P vs. PPN; reported separately). Side effects were assessed (CTCAE and RTOG) up to 18 weeks after starting radiotherapy (early effects) and 6-monthly for first 2 years. Follow-up continues for late side effects (descriptive analysis presented) and data from the “boost” comparisons of the PIVOTALboost trial1 (ISRCTN80146950) Material/Methods:
Conclusion: SBRT to the prostate and pelvis is non-inferior and not significantly different from MHRT for key QoL parameters in the first year of treatment for high-risk and node-positive prostate cancer. Keywords: SBRT, hypofractionation, prostate cancer
Proffered Paper 1751
Moderately fractionated prostate radiotherapy with a focal boost: acute and preliminary late side effects from the phase 3 PIVOTALboost trial Isabel Syndikus 1 , Elizabeth Limb 2 , Alison Tree 3 , Ann Henry 4 , John Staffurth 5 , Helen Mayles 6 , Olivia Naismith 7 , Anjali Zarkar 8 , Anna Lydon 9 , Gail Horan 10 , John Frew 11 , Mausam Singhera 12 , Miguel Panades 13 , Nick Everritt 2 , Peter Ostler 14 , Peter Bownes 15 , Peter Hoskin 14 , Ramachandran Venkitaraman 16 , Shama
Made with FlippingBook - Share PDF online